09 Sep 2017 |
ESMO 2017: TIL Levels Signal Pembrolizumab Response in Metastatic TNBC |
Breast cancer -
Cancer Immunology and Immunotherapy |
09 Sep 2017 |
ESMO 2017: Promising Response Rates in Patients with Metastatic TNBC Treated with Nivolumab After Induction Treatment |
Breast cancer -
Cancer Immunology and Immunotherapy |
09 Sep 2017 |
ESMO 2017: Promising Results Demonstrated with DCC-2618 in GIST |
Sarcomas -
Anticancer agents & Biologic therapy |
09 Sep 2017 |
ESMO 2017: Overall Survival Benefit is Seen with Olaparib in Patients with Ovarian Cancer and TP53 Disruptive Mutation Status |
Gynaecologic malignancies -
Anticancer agents & Biologic therapy |
09 Sep 2017 |
ESMO 2017: Progression-free Rate Unaffected by Sequence of Cytoreductive Nephrectomy and Sunitinib in Patients with Synchronous mRCC |
Genitourinary cancers -
Anticancer agents & Biologic therapy |
08 Sep 2017 |
ESMO 2017: Combined Nivolumab and Radiotherapy ± Temozolomide Is Safe in Patients With Newly Diagnosed Glioblastoma |
Central nervous system malignancies -
Cancer Immunology and Immunotherapy |
08 Sep 2017 |
ESMO 2017: PD-L1 as a Prognostic Factor in Patients with Glioblastoma |
Central nervous system malignancies -
Pathology/Molecular biology |
08 Sep 2017 |
ESMO 2017: Rucaparib Shows Clinical Benefit as Maintenance Therapy in Patients with Recurrent Ovarian Cancer |
Gynaecologic malignancies -
Anticancer agents & Biologic therapy |
08 Sep 2017 |
ESMO 2017: Patients with Platinum Sensitive Ovarian Cancer Maintan QoL During Maintenance Niraparib Therapy |
Gynaecologic malignancies -
Anticancer agents & Biologic therapy |
08 Sep 2017 |
ESMO 2017: Adding Abiraterone Acetate or Docetaxel Plus Prednisone to Standard of Care in Patients with High-Risk Prostate Cancer |
Genitourinary cancers -
Anticancer agents & Biologic therapy |
08 Sep 2017 |
ESMO 2017: Germline Mutations in DNA Repair Genes Lowers Survival in mCRPC |
Genitourinary cancers -
Translational research |
08 Sep 2017 |
ESMO 2017: Significant Clinical Activity Demonstrated with 177Lu-PSMA617 in mCRPC |
Genitourinary cancers |
08 Sep 2017 |
ESMO 2017: Combined Taselisib and Letrozole Improves Response in Postmenopausal Women with ER-positive, HER-negative Early Breast Cancer |
Breast cancer -
Anticancer agents & Biologic therapy |
08 Sep 2017 |
ESMO 2017: Invasive DFS Rates Following Trastuzumab are Improved with Neratinib Over Placebo in Early Stage HER2-positive Breast Cancer |
Breast cancer -
Anticancer agents & Biologic therapy |
08 Sep 2017 |
ESMO 2017: Pembrolizumab Demonstrates Antitumour Activity in Advanced Gastric Cancer as Monotherapy and Combined with Chemotherapy |
Gastrointestinal cancers -
Anticancer agents & Biologic therapy |